Neurology® Podcast

Delayed Recall - June 2017In this special Delayed Recall episode, Dr. Luca Bartolini speaks with epilepsy experts Dr. Greg Cascino, Dr. Ali Asadi-Pooya, and Dr. Ley Sander. They discuss the results of a recent Practice Current (a section of Neurology® Clinical Practice) survey regarding antiepileptic drug discontinuation, and share their thoughts on best practices with regard to the case studies presented to the survey respondents. This is the first appearance of this interview in the podcast.

We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 3 and 4, Dr. Andy Southerland interviews Dr. Gary Franklin. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.

Show description/summary:1) Post-stroke epilepsy in long-term survivors of primary intracerebral hemorrhage2) Neurology Today® paper on migraine and young adults' risk of cervical artery dissectionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 6, 2017 issue of Neurology. In the first segment, Dr. Rahul Guha talks with Dr. Anna-Maija Lahti about her paper on post-stroke epilepsy in long-term survivors of primary intracerebral hemorrhage. In the next part of the podcast Dr. Andrew Southerland talks with Dr. Valeria De Giuli about a Neurology Today® story on migraine and young adults' risk of cervical artery dissection. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review.All other participants report no disclosures.

Show description/summary:1) Evidence-based guideline summary: Reducing brain injury following cardiopulmonary resuscitation2) Neurology Today® paper: "Prolonged Holter-ECG monitoring found to improve detection of atrial fibrillation after acute stroke"This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 30, 2017 issue of Neurology. In the first segment, Dr. Andrew Schomer talks with Dr. Romergryko Geocadin about the AAN practice guideline on reducing brain injury following cardiopulmonary resuscitation. In the next part of the podcast Dr. Matthew Ehrlich focuses his interview with Dr. Rolf Wachter on the Neurology Today feature, "Prolonged Holter-ECG monitoring found to improve detection of atrial fibrillation after acute stroke." Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Geocadin serves on the DSMB for the PEARL Study: "A Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography for Post-Cardiac Arrest Patients with No ST Segment Elevation on the ECG" funded by the State of Arizona Biomedical Research Commission; serves on editorial boards for Neurocritical Care and Resuscitation; receives research support from NIH (grant R01 HL071568); and is co-author of "Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care."All other participants report no disclosures.

Show description/summary:1) A randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study2) What's Trending: Survival and dementia in GBA-associated Parkinson disease This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 23, 2017 issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Hubert Fernandez about his paper on deutetrabenazine for tardive dyskinesia. For our "What's Trending" feature of the week, Dr. Alberto Espay talks with Dr. Roberto Cilia about his Annals of Neurology paper on survival and dementia in GBA-associated Parkinson disease. Disclosures can be found at Neurology.org. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Barrett receives research support from Axovant Sciences, Inc., Azevan Pharmaceuticals, Merck Sharp & Dohme Corp, Virginia Center of Alzheimer´s and Related Diseases, Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Program, and NIH.Dr. Fernandez serves on scientific advisory boards for Solvay Duodopa Global Study, EMD Serono Safinamide Global Study, and the Xeomin Registry (all uncompensated); has received travel or speaker honoraria from USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, US World Meds, Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carline Communications, Medscape, Biogen GE Healthcare, Lundbeck, and Pfizer; served as Medical Editor for the Movement Disorders Society; co-owns the patent for COMPRESS; receives royalty payments from book publications with Demos Publishing, Manson Publishing, and Springer Publishing; has received research support from AbbVie, Acadia, Teva Pharmaceuticals, Biotie Therapeutics, Civitas, Kyowa Kirin International, Rhythm Pharmaceuticals, Synosia Therapeutics, Abbott, Merz Pharmaceuticals, Xeomin Registry Study, Ipsen Pharmaceuticals, Michael J. Fox Foundation, Movement Disorders Society, Huntington Study Group, Parkinson Study Group, National Parkinson Foundation, Society of Progressive Supranuclear Palsy, and NIH/NINDS.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Cilia receives research support from Fondazione Grigioni per il Morbo di Parkinson.

We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 3 and 4, Dr. Andy Southerland interviews Dr. Gary Franklin from the University of Washington. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.

Show description/summary:1) Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE2) Neurology Today® paper on a new guideline for preventing, diagnosing, and treating diabetic neuropathyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 16, 2017 issue of Neurology. In the first segment, Dr. Justin Sattin talks with Dr. Yilong Wang about his paper on risks and benefits of clopidogrel-aspirin in minor stroke. In the next part of the podcast Dr. Michelle Mauermann focuses her interview with Dr. Rodica Pop-Busui on diabetic neuropathy. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Wang receives research support from the Ministry of Science and Technology of the People's Republic of China (No. 2011BAI08B02) and the National Natural Science Foundation of China (No. 81322019).Dr. Mauermann serves on the editorial board for Mayo Clinic Proceedings; receives publishing royalties from Autonomic Neurology (Oxford 2015); and receives research support from Ionis Pharmaceuticals, Inc., and Alnylam Pharmaceauticals.All other participants report no disclosures.

Show description/summary:1) Serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports2) What's Trending: Biomarker validation and precision medicine in Parkinson disease.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 9, 2017 issue of Neurology. In the first segment, Dr. Kristen Heinan talks with Dr. Pashtun Shahim about his paper on serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports. In the next part of the podcast Dr. Alberto Espay focuses his discussion with Dr. David Standaert on biomarker validation and precision medicine in Parkinson disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Standaert serves on scientific advisory boards for the American Parkinson Disease Association; serves on the DSMB for Shire/Biropharma; received honoraria from the Movement Disorder Society and Georgia Regents University; is Associate Editor for Movement Disorders; receives publishing royalties for Movement Disorders (McGraw-Hill Publishers, 3rd ed.); consulted for Serina Therapeutics, Kirchner Group, Teva Neuroscience, Abbvie, and the U.S. Attorney's Office; receives research support from Abbvie, Acerta Pharmaceuticals, Ceregene, Quintiles, NIH, Alabama Department of Commerce, American Parkinson Disease Association, Michael J. Fox Foundation for Parkinson Research, Bachmann-Strauss Dystonia & Parkinson Foundation, and the Dystonia Medical Research Foundation.All other participants report no disclosures.

We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 1 and 2, Dr. Ted Burns interviews Dr. Charles Argoff from Albany Medical College in New York. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.

We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 1 and 2, Dr. Ted Burns interviews Dr. Charles Argoff from Albany Medical College in New York. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.